

Michael Ploug

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8241704/publications.pdf>

Version: 2024-02-01

131
papers

6,425
citations

41344

49
h-index

74163

75
g-index

134
all docs

134
docs citations

134
times ranked

4715
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasminogen activation and cancer. <i>Thrombosis and Haemostasis</i> , 2005, 93, 676-681.	3.4	398
2	Structure-function relationships in the receptor for urokinase-type plasminogen activator Comparison to other members of the Ly-6 family and snake venom β -neurotoxins. <i>FEBS Letters</i> , 1994, 349, 163-168.	2.8	231
3	Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. <i>EMBO Journal</i> , 2005, 24, 1655-1663.	7.8	213
4	Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. <i>FEBS Letters</i> , 1991, 288, 233-236.	2.8	177
5	Peptide-Derived Antagonists of the Urokinase Receptor. Affinity Maturation by Combinatorial Chemistry, Identification of Functional Epitopes, and Inhibitory Effect on Cancer Cell Intravasation. <i>Biochemistry</i> , 2001, 40, 12157-12168.	2.5	170
6	Intramolecular Migration of Amide Hydrogens in Protonated Peptides upon Collisional Activation. <i>Journal of the American Chemical Society</i> , 2005, 127, 2785-2793.	13.7	161
7	Structure-Function Relationships in the Interaction Between the Urokinase-Type Plasminogen Activator and Its Receptor. <i>Current Pharmaceutical Design</i> , 2003, 9, 1499-1528.	1.9	153
8	The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. <i>FEBS Letters</i> , 1997, 420, 79-85.	2.8	131
9	Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. <i>EMBO Journal</i> , 2006, 25, 2686-2697.	7.8	120
10	Ligand Interaction between Urokinase-Type Plasminogen Activator and Its Receptor Probed with 8-Anilino-1-naphthalenesulfonate. Evidence for a Hydrophobic Binding Site Exposed Only on the Intact Receptor. <i>Biochemistry</i> , 1994, 33, 8991-8997.	2.5	113
11	Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2017, 376, 1647-1658.	27.0	112
12	Protein Structure and Membrane Anchorage of the Cellular Receptor for Urokinase-Type Plasminogen Activator. <i>Seminars in Thrombosis and Hemostasis</i> , 1991, 17, 183-193.	2.7	111
13	A Region in Urokinase Plasminogen Receptor Domain III Controlling a Functional Association with β 1 Integrin and Tumor Growth. <i>Journal of Biological Chemistry</i> , 2006, 281, 14852-14863.	3.4	110
14	The Urokinase Receptor as a Potential Target in Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2004, 10, 2359-2376.	1.9	110
15	<i>Plasmodium</i> ookinetes coopt mammalian plasminogen to invade the mosquito midgut. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17153-17158.	7.1	109
16	The Murine Receptor for Urokinase-Type Plasminogen Activator Is Primarily Expressed in Tissues Actively Undergoing Remodeling. <i>Journal of Histochemistry and Cytochemistry</i> , 2001, 49, 237-246.	2.5	106
17	First-in-human uPAR PET: Imaging of Cancer Aggressiveness. <i>Theranostics</i> , 2015, 5, 1303-1316.	10.0	92
18	On the mechanism of angiotensin-like protein 8 for control of lipoprotein lipase activity. <i>Journal of Lipid Research</i> , 2019, 60, 783-793.	4.2	92

#	ARTICLE	IF	CITATIONS
19	Mapping of the Vitronectin-binding Site on the Urokinase Receptor. <i>Journal of Biological Chemistry</i> , 2007, 282, 13561-13572.	3.4	88
20	GPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism. <i>Cell Metabolism</i> , 2019, 30, 51-65.	16.2	86
21	Photoaffinity Labeling of the Human Receptor for Urokinase-Type Plasminogen Activator Using a Decapeptide Antagonist. Evidence for a Composite Ligand-Binding Site and a Short Interdomain Separation. <i>Biochemistry</i> , 1998, 37, 3612-3622.	2.5	78
22	Characterization of the Functional Epitope on the Urokinase Receptor. <i>Journal of Biological Chemistry</i> , 2006, 281, 19260-19272.	3.4	78
23	Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. <i>Blood</i> , 2010, 116, 1593-1603.	1.4	78
24	The angiopoietin-like protein ANGPTL4 catalyzes unfolding of the hydrolase domain in lipoprotein lipase and the endothelial membrane protein GPIHBP1 counteracts this unfolding. <i>ELife</i> , 2016, 5, .	6.0	78
25	The PCNA interaction motifs revisited: thinking outside the PIP-box. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4923-4943.	5.4	77
26	The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain. <i>ELife</i> , 2016, 5, e12095.	6.0	74
27	Imaging of Urokinase-Type Plasminogen Activator Receptor Expression Using a ⁶⁴ Cu-Labeled Linear Peptide Antagonist by microPET. <i>Clinical Cancer Research</i> , 2008, 14, 4758-4766.	7.0	73
28	Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with ⁶⁴ Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion. <i>Journal of Nuclear Medicine</i> , 2012, 53, 138-145.	5.0	73
29	Structure-based Engineering of Species Selectivity in the Interaction between Urokinase and Its Receptor. <i>Journal of Biological Chemistry</i> , 2010, 285, 10982-10992.	3.4	68
30	Mapping Part of the Functional Epitope for Ligand Binding on the Receptor for Urokinase-type Plasminogen Activator by Site-directed Mutagenesis. <i>Journal of Biological Chemistry</i> , 1999, 274, 37995-38003.	3.4	67
31	Administration of Recombinant Soluble Urokinase Receptor Per Se Is Not Sufficient to Induce Podocyte Alterations and Proteinuria in Mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1662-1668.	6.1	67
32	GPIHBP1 and Plasma Triglyceride Metabolism. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 455-469.	7.1	67
33	Structure of the lipoprotein lipase-GPIHBP1 complex that mediates plasma triglyceride hydrolysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1723-1732.	7.1	67
34	A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. <i>FEBS Journal</i> , 1992, 208, 397-404.	0.2	66
35	Chemical Modification of the Urokinase-Type Plasminogen Activator and Its Receptor Using Tetranitromethane. Evidence for the Involvement of Specific Tyrosine Residues in Both Molecules during Receptor-Ligand Interaction. <i>Biochemistry</i> , 1995, 34, 12524-12534.	2.5	65
36	Glycosylation Profile of a Recombinant Urokinase-type Plasminogen Activator Receptor Expressed in Chinese Hamster Ovary Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 13933-13943.	3.4	62

#	ARTICLE	IF	CITATIONS
37	Specific Immunoassays for Detection of Intact and Cleaved Forms of the Urokinase Receptor. <i>Clinical Chemistry</i> , 2004, 50, 2059-2068.	3.2	60
38	Lipoprotein lipase is active as a monomer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6319-6328.	7.1	60
39	Identification of Specific Sites Involved in Ligand Binding by Photoaffinity Labeling of the Receptor for the Urokinase-Type Plasminogen Activator. Residues Located at Equivalent Positions in uPAR Domains I and III Participate in the Assembly of a Composite Ligand-Binding Site. <i>Biochemistry</i> , 1998, 37, 16494-16505.	2.5	58
40	Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor. <i>Biochemical Journal</i> , 2004, 380, 845-857.	3.7	58
41	Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. <i>FEBS Journal</i> , 1992, 205, 451-458.	0.2	57
42	Structure and ligand interactions of the urokinase receptor (uPAR). <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 5441.	3.0	57
43	Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in <i>Drosophila Schneider 2</i> cells after deletion of glycosylation-sites. <i>Protein Expression and Purification</i> , 2004, 34, 284-295.	1.3	56
44	Unfolding of monomeric lipoprotein lipase by ANGPTL4: Insight into the regulation of plasma triglyceride metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4337-4346.	7.1	56
45	Dynamics of Urokinase Receptor Interaction with Peptide Antagonists Studied by Amide Hydrogen Exchange and Mass Spectrometry. <i>Biochemistry</i> , 2004, 43, 15044-15057.	2.5	54
46	Tousled-like kinases phosphorylate Asf1 to promote histone supply during DNA replication. <i>Nature Communications</i> , 2014, 5, 3394.	12.8	54
47	NanoSIMS Analysis of Intravascular Lipolysis and Lipid Movement across Capillaries and into Cardiomyocytes. <i>Cell Metabolism</i> , 2018, 27, 1055-1066.e3.	16.2	54
48	Conformational Regulation of Urokinase Receptor Function. <i>Journal of Biological Chemistry</i> , 2011, 286, 33544-33556.	3.4	51
49	⁶⁸ Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. <i>Nuclear Medicine and Biology</i> , 2012, 39, 560-569.	0.6	51
50	Electrochemical Reduction of Disulfide-Containing Proteins for Hydrogen/Deuterium Exchange Monitored by Mass Spectrometry. <i>Analytical Chemistry</i> , 2014, 86, 340-345.	6.5	51
51	A disordered acidic domain in GPIHBP1 harboring a sulfated tyrosine regulates lipoprotein lipase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6020-E6029.	7.1	51
52	Improved PET Imaging of uPAR Expression Using new ⁶⁴ Cu-labeled Cross-Bridged Peptide Ligands: Comparative in vitro and in vivo Studies. <i>Theranostics</i> , 2013, 3, 618-632.	10.0	50
53	GPIHBP1 Missense Mutations Often Cause Multimerization of GPIHBP1 and Thereby Prevent Lipoprotein Lipase Binding. <i>Circulation Research</i> , 2015, 116, 624-632.	4.5	50
54	Multimerization of Glycosylphosphatidylinositol-anchored High Density Lipoprotein-binding Protein 1 (GPIHBP1) and Familial Chylomicronemia from a Serine-to-Cysteine Substitution in GPIHBP1 Ly6 Domain. <i>Journal of Biological Chemistry</i> , 2014, 289, 19491-19499.	3.4	45

#	ARTICLE	IF	CITATIONS
55	Plasminogen-Independent Initiation of the Pro-urokinase Activation Cascade in Vivo. Activation of Pro-urokinase by Glandular Kallikrein (mGK-6) in Plasminogen-Deficient Mice. <i>Biochemistry</i> , 2000, 39, 508-515.	2.5	44
56	A Flexible Multidomain Structure Drives the Function of the Urokinase-type Plasminogen Activator Receptor (uPAR)*. <i>Journal of Biological Chemistry</i> , 2012, 287, 34304-34315.	3.4	43
57	Crystal Structure of the Urokinase Receptor in a Ligand-Free Form. <i>Journal of Molecular Biology</i> , 2012, 416, 629-641.	4.2	42
58	Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer. <i>Lung Cancer</i> , 2007, 58, 260-266.	2.0	37
59	Collisional Activation by MALDI Tandem Time-of-flight Mass Spectrometry Induces Intramolecular Migration of Amide Hydrogens in Protonated Peptides. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 1910-1919.	3.8	36
60	New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using ¹⁷⁷ Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. <i>Nuclear Medicine and Biology</i> , 2012, 39, 962-969.	0.6	36
61	Altered expression of the urokinase receptor homologue, C4.4A, in invasive areas of human esophageal squamous cell carcinoma. <i>International Journal of Cancer</i> , 2008, 122, 734-741.	5.1	35
62	Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105. <i>PLoS ONE</i> , 2016, 11, e0147428.	2.5	35
63	A new tagging system for production of recombinant proteins in <i>Drosophila</i> S2 cells using the third domain of the urokinase receptor. <i>Protein Expression and Purification</i> , 2007, 52, 384-394.	1.3	34
64	uPAR Targeted Radionuclide Therapy with ¹⁷⁷ Lu-DOTA-AE105 Inhibits Dissemination of Metastatic Prostate Cancer. <i>Molecular Pharmaceutics</i> , 2014, 11, 2796-2806.	4.6	34
65	[13] Cellular receptor for urokinase-type plasminogen activator: Protein structure. <i>Methods in Enzymology</i> , 1993, 223, 207-222.	1.0	33
66	Mobility of α -HSPG-bound LPL explains how LPL is able to reach GPIHBP1 on capillaries. <i>Journal of Lipid Research</i> , 2017, 58, 216-225.	4.2	33
67	The Importance of Lipoprotein Lipase Regulation in Atherosclerosis. <i>Biomedicines</i> , 2021, 9, 782.	3.2	33
68	Solution structure of recombinant somatomedin B domain from vitronectin produced in <i>Pichia pastoris</i> . <i>Protein Science</i> , 2007, 16, 1934-1945.	7.6	32
69	Origin and diversification of the plasminogen activation system among chordates. <i>BMC Evolutionary Biology</i> , 2019, 19, 27.	3.2	31
70	Hydrogen/Deuterium Exchange Mass Spectrometry Reveals Specific Changes in the Local Flexibility of Plasminogen Activator Inhibitor 1 upon Binding to the Somatomedin B Domain of Vitronectin. <i>Biochemistry</i> , 2012, 51, 8256-8266.	2.5	29
71	Evolution and Medical Significance of LU Domain-Containing Proteins. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2760.	4.1	29
72	The intrinsic instability of the hydrolase domain of lipoprotein lipase facilitates its inactivation by ANGPTL4-catalyzed unfolding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	29

#	ARTICLE	IF	CITATIONS
73	Mimicry of the Regulatory Role of Urokinase in Lamellipodia Formation by Introduction of a Non-native Interdomain Disulfide Bond in Its Receptor. <i>Journal of Biological Chemistry</i> , 2011, 286, 43515-43526.	3.4	28
74	Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells. <i>Nanoscale</i> , 2013, 5, 8192.	5.6	28
75	Structure-Driven Design of Radionuclide Tracers for Non-Invasive Imaging of uPAR and Targeted Radiotherapy. The Tale of a Synthetic Peptide Antagonist. <i>Theranostics</i> , 2013, 3, 467-476.	10.0	28
76	Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 483-494.	2.5	28
77	One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry. <i>Protein Expression and Purification</i> , 2007, 52, 286-296.	1.3	27
78	Hydrogen atom scrambling in selectively labeled anionic peptides upon collisional activation by MALDI tandem time-of-flight mass spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2008, 19, 1719-1725.	2.8	27
79	Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: Inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. <i>Thrombosis and Haemostasis</i> , 2007, 97, 1013-1022.	3.4	26
80	A Composite Role of Vitronectin and Urokinase in the Modulation of Cell Morphology upon Expression of the Urokinase Receptor. <i>Journal of Biological Chemistry</i> , 2008, 283, 15217-15223.	3.4	26
81	Stabilizing a Flexible Interdomain Hinge Region Harboring the SMB Binding Site Drives uPAR into Its Closed Conformation. <i>Journal of Molecular Biology</i> , 2015, 427, 1389-1403.	4.2	25
82	GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 964-971.	1.5	25
83	Neutralisation of uPA with a Monoclonal Antibody Reduces Plasmin Formation and Delays Skin Wound Healing in tPA-Deficient Mice. <i>PLoS ONE</i> , 2010, 5, e12746.	2.5	25
84	The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities. <i>Cancers</i> , 2021, 13, 5376.	3.7	24
85	GPIHBP1 and ANGPTL4 Utilize Protein Disorder to Orchestrate Order in Plasma Triglyceride Metabolism and Regulate Compartmentalization of LPL Activity. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 702508.	3.7	22
86	Ly6/uPAR-Related Protein C4.4A as a Marker of Solid Growth Pattern and Poor Prognosis in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 152-160.	1.1	21
87	Chylomicronemia from GPIHBP1 autoantibodies. <i>Journal of Lipid Research</i> , 2020, 61, 1365-1376.	4.2	21
88	Interactions of Plasminogen Activator Inhibitor-1 with Vitronectin Involve an Extensive Binding Surface and Induce Mutual Conformational Rearrangements. <i>Biochemistry</i> , 2009, 48, 1723-1735.	2.5	20
89	The Urokinase Receptor Homolog Haldisin Is a Novel Differentiation Marker of Stratum Granulosum in Squamous Epithelia. <i>Journal of Histochemistry and Cytochemistry</i> , 2013, 61, 802-813.	2.5	19
90	Protein-Binding RNA Aptamers Affect Molecular Interactions Distantly from Their Binding Sites. <i>PLoS ONE</i> , 2015, 10, e0119207.	2.5	19

#	ARTICLE	IF	CITATIONS
91	Expression of C4.4A, a Structural uPAR Homolog, Reflects Squamous Epithelial Differentiation in the Adult Mouse and during Embryogenesis. <i>Journal of Histochemistry and Cytochemistry</i> , 2011, 59, 188-201.	2.5	18
92	ANGPTL4 inactivates lipoprotein lipase by catalyzing the irreversible unfolding of LPL's hydrolase domain. <i>Journal of Lipid Research</i> , 2020, 61, 1253.	4.2	16
93	Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 732015.	3.7	16
94	Targeting Tumor Cell Invasion and Dissemination <i>In Vivo</i> by an Aptamer That Inhibits Urokinase-type Plasminogen Activator through a Novel Multifunctional Mechanism. <i>Molecular Cancer Research</i> , 2012, 10, 1532-1543.	3.4	15
95	Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma. <i>International Journal of Cancer</i> , 2012, 130, 2734-2739.	5.1	15
96	Monoclonal antibodies that bind to the Ly6 domain of GPIHBP1 abolish the binding of LPL. <i>Journal of Lipid Research</i> , 2017, 58, 208-215.	4.2	15
97	An enzyme-linked immunosorbent assay for measuring GPIHBP1 levels in human plasma or serum. <i>Journal of Clinical Lipidology</i> , 2018, 12, 203-210.e1.	1.5	15
98	GPIHBP1 autoantibody syndrome during interferon β 21a treatment. <i>Journal of Clinical Lipidology</i> , 2019, 13, 62-69.	1.5	15
99	Peptide Disc Mediated Control of Membrane Protein Orientation in Supported Lipid Bilayers for Surface-Sensitive Investigations. <i>Analytical Chemistry</i> , 2020, 92, 1081-1088.	6.5	14
100	Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography. <i>Data in Brief</i> , 2015, 5, 107-113.	1.0	13
101	Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies. <i>Journal of Clinical Lipidology</i> , 2020, 14, 197-200.	1.5	13
102	Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. <i>Thrombosis and Haemostasis</i> , 2007, 97, 1013-22.	3.4	13
103	Electrostatic sheathing of lipoprotein lipase is essential for its movement across capillary endothelial cells. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	13
104	Expression of the Ly6/uPAR-Domain Proteins C4.4A and Haldisin in Non-Invasive and Invasive Skin Lesions. <i>Journal of Histochemistry and Cytochemistry</i> , 2015, 63, 142-154.	2.5	12
105	Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?. <i>Journal of Biological Chemistry</i> , 2019, 294, 7403-7418.	3.4	11
106	Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report. <i>Annals of Internal Medicine</i> , 2020, 173, 764-765.	3.9	11
107	The structural basis for monoclonal antibody 5D2 binding to the tryptophan-rich loop of lipoprotein lipase. <i>Journal of Lipid Research</i> , 2020, 61, 1347-1359.	4.2	11
108	IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts. <i>Theranostics</i> , 2021, 11, 7159-7174.	10.0	11

#	ARTICLE	IF	CITATIONS
109	An LPL-specific monoclonal antibody, 88B8, that abolishes the binding of LPL to GPIHBP1. <i>Journal of Lipid Research</i> , 2016, 57, 1889-1898.	4.2	10
110	C4.4A gene ablation is compatible with normal epidermal development and causes modest overt phenotypes. <i>Scientific Reports</i> , 2016, 6, 25833.	3.3	10
111	Specific recognition of the C-terminal end of A β 242 by a high affinity monoclonal antibody. <i>Molecular Immunology</i> , 2009, 46, 2267-2273.	2.2	9
112	Small-Molecule Inhibition of the uPAR-uPA Interaction by Conformational Selection. <i>ChemMedChem</i> , 2021, 16, 377-387.	3.2	9
113	ANGPTL4 sensitizes lipoprotein lipase to PCSK3 cleavage by catalyzing its unfolding. <i>Journal of Lipid Research</i> , 2021, 62, 100071.	4.2	9
114	ANGPTL4: a new mode in the regulation of intravascular lipolysis. <i>Current Opinion in Lipidology</i> , 2022, 33, 112-119.	2.7	9
115	Urokinase-type Plasminogen Activator-like Proteases in Teleosts Lack Genuine Receptor-binding Epidermal Growth Factor-like Domains. <i>Journal of Biological Chemistry</i> , 2012, 287, 27526-27536.	3.4	8
116	C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma. <i>World Journal of Clinical Oncology</i> , 2014, 5, 621.	2.3	8
117	Determination of Binding Kinetics of Intrinsically Disordered Proteins by Surface Plasmon Resonance. <i>Methods in Molecular Biology</i> , 2020, 2141, 611-627.	0.9	8
118	Expression and one-step purification of active LPL contemplated by biophysical considerations. <i>Journal of Lipid Research</i> , 2021, 62, 100149.	4.2	7
119	Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer. <i>Molecular Carcinogenesis</i> , 2016, 55, 717-731.	2.7	6
120	<i>Helicobacter pylori</i> Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis. <i>Microorganisms</i> , 2020, 8, 1019.	3.6	5
121	Crystal structure of the unoccupied murine urokinase-type plasminogen activator receptor (uPAR) reveals a tightly packed DII-DIII unit. <i>FEBS Letters</i> , 2019, 593, 1236-1247.	2.8	4
122	Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR-Neurotoxin Domain. <i>International Journal of Biological Sciences</i> , 2020, 16, 981-993.	6.4	4
123	Disorder in a two-domain neuronal Ca ²⁺ -binding protein regulates domain stability and dynamics using ligand mimicry. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 2263-2278.	5.4	4
124	Expression of C4.4A in an In Vitro Human Tissue-Engineered Skin Model. <i>BioMed Research International</i> , 2017, 2017, 1-9.	1.9	3
125	Efficient refolding and reconstitution of tissue factor into nanodiscs facilitates structural investigation of a multicomponent system on a lipid bilayer. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2020, 1862, 183214.	2.6	3
126	Optimization and Evaluation of Al ¹⁸ F Labeling Using a NOTA or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR. <i>Frontiers in Nuclear Medicine</i> , 2021, 1, .	1.2	2

#	ARTICLE	IF	CITATIONS
127	Expression and crystallographic studies of the D1D2 domains of C4.4A, a homologous protein to the urokinase receptor. Acta Crystallographica Section F, Structural Biology Communications, 2017, 73, 486-490.	0.8	1
128	17 Identification of potential target sites on the urokinase-receptor for use in antagonist-based anti-cancer therapy. Apmis, 2008, 116, 425-426.	2.0	0
129	Abstract 5237: Non-invasive detection of urokinase-type plasminogen activator receptor (uPAR) expression in four human cancer xenograft mouse models using microPET/CT. , 2010, , .		0
130	Abstract 5280: PET imaging of proteolysis: Evaluation of 68Ga-DOTA and 68Ga-NODAGA chelates of an uPAR-specific peptide in a human glioblastoma xenograft model. , 2011, , .		0
131	Gene Expression and Function of the Cellular Receptor for u-PA (u-PAR). , 2019, , 30-42.		0